Forty three Eighteen Advisors LLC Takes $2.63 Million Position in Merck & Co., Inc. $MRK

Key Points

• Forty three Eighteen Advisors LLC opened a new position in Merck during the first quarter, buying 21,894 shares valued at about $2.63 million. The stake makes Merck its 14th largest holding and represents about 2.0% of the fund’s portfolio.
• Wall Street remains broadly positive on Merck, with several firms raising or reaffirming targets; the stock currently carries a Moderate Buy consensus and a consensus price target of $133.94.
• Merck recently beat quarterly earnings and revenue expectations, and it also paid a $0.85 quarterly dividend for a 2.7% annualized yield. The company is benefiting from progress in its pipeline and a new FDA-approved cholesterol drug, LIPFENDRA, which could broaden growth beyond Keytruda.

Forty three Eighteen Advisors LLC purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 21,894 shares of the company's stock, valued at approximately $2,634,000. Merck & Co., Inc. accounts for approximately 2.0% of Forty three Eighteen Advisors LLC's holdings, making the stock its 14th biggest position.

Other institutional investors also recently bought and sold shares of the company. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. during the 4th quarter valued at approximately $25,000. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $26,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $26,000. IFC & Insurance Marketing Inc. purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $31,000. Finally, High Note Wealth LLC lifted its stake in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock valued at $31,000 after purchasing an additional 109 shares during the period. 76.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MRK has been the topic of several research reports. Royal Bank Of Canada restated an "outperform" rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Weiss Ratings downgraded Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a report on Friday, May 15th. Guggenheim raised their price objective on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a "buy" rating in a research report on Monday, July 13th. CICC Research began coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 target price on the stock. Finally, Scotiabank upped their target price on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $133.94.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $127.47 on Friday. The company has a market capitalization of $314.83 billion, a price-to-earnings ratio of 35.91, a price-to-earnings-growth ratio of 4.40 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company's 50-day moving average is $120.11 and its 200 day moving average is $116.94. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $131.74.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.'s revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts expect that Merck & Co., Inc. will post 3.17 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Monday, June 15th. Merck & Co., Inc.'s dividend payout ratio is 95.77%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approval of LIPFENDRA gives Merck its first oral PCSK9 inhibitor, opening a new revenue stream in cardiovascular care and strengthening its non-oncology portfolio. Reuters article on FDA approval
• Positive Sentiment: Analysts highlighted continued oncology pipeline progress, including FDA acceptance of multiple regulatory filings and Merck’s broader effort to offset the eventual 2028 Keytruda patent cliff. Seeking Alpha article on pipeline expansion
• Neutral Sentiment: Coverage also noted that Lipfendra’s launch is expected soon and that the drug could become a major product over time, though sales will depend on uptake, pricing, and competition from existing cholesterol therapies. Zacks article on Lipfendra launch
• Neutral Sentiment: There was also a rumor that Merck may be in a takeover battle for genomics company Personalis, but this appears speculative and is not confirmed. Yahoo Finance article on Personalis rumor

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.